Back to search
Marginal Zone Lymphoma(MZL)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Marginal Zone Lymphoma(MZL) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Marginal Zone Lymphoma(MZL) trials you may qualify forThis study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on partic…
Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphoc…
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/re…
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monoth…
This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphom…
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the…
This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned…
For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qual…